The HiLo Trial: a Multicentre Randomised Trial of High- versus Low-dose Radioiodine, with or without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation after Surgery for Differentiated Thyroid Cancer

2008 ◽  
Vol 20 (5) ◽  
pp. 325-326 ◽  
Author(s):  
U. Mallick ◽  
C. Harmer ◽  
A. Hackshaw
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Low Dose ◽  
Randomised Trial ◽  
Thyroid Stimulating Hormone ◽  
Human Thyroid ◽  
Remnant Ablation ◽  
Stimulating Hormone

scholarly journals Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Robert M. Wolfson ◽  
Irina Rachinsky ◽  
Deric Morrison ◽  
Al Driedger ◽  
Tamara Spaic ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Metastatic Disease ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Thyroid Stimulating Hormone ◽  
Human Thyroid ◽  
Thyroid Hormone Withdrawal ◽  
Significant Difference ◽  
Stimulating Hormone

Introduction.Recombinant human thyroid stimulating hormone (rhTSH) is approved for preparation of thyroid remnant ablation with radioactive iodine (RAI) in low risk patients with well differentiated thyroid cancer (DTC). We studied the safety and efficacy of rhTSH preparation for RAI treatment of thyroid cancer patients with nodal metastatic disease.Methods.A retrospective analysis was performed on 108 patients with histopathologically confirmed nodal metastatic DTC, treated with initial RAI between January 1, 2000, and December 31, 2007. Within this selected group, 31 and 42 patients were prepared for initial and all subsequent RAI treatments by either thyroid hormone withdrawal (THW) or rhTSH protocols and were followed up for at least 3 years.Results.The response to initial treatment, classified as excellent, acceptable, or incomplete, was not different between the rhTSH group (57%, 21%, and 21%, resp.) and the THW group (39%, 13%, and 48%, resp.;P=0.052). There was no significant difference in the final clinical outcome between the groups. The rhTSH group received significantly fewer additional doses of RAI than the THW group (P=0.03).Conclusion.In patients with nodal-positive DTC, preparation for RAI with rhTSH is a safe and efficacious alternative to THW protocol.

scholarly journals Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone

Medicine ◽  
2015 ◽  
Vol 94 (39) ◽  
pp. e1490
Author(s):  
Keisuke Enomoto ◽  
Yoshiharu Sakata ◽  
Kazuyuki Izumi ◽  
Yukinori Takenaka ◽  
Miki Nagai ◽  
...  
Keyword(s):  
Low Dose ◽  
Thyroid Stimulating Hormone ◽  
Human Thyroid ◽  
Remnant Ablation ◽  
Radioiodine Remnant Ablation ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document